Christine Velicer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christine Velicer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alfred J. Saah
Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
2 shared publications Alfred Saah
Merck & Co., Inc., Kenilworth, NJ, USA
2 shared publicationsAlain Luxembourg
Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication- Alain Luxembourg
Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication - Alain Luxembourg
Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
1 shared publication - Andres Gomez-Lievano
Analysis Group, Inc., Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use
- Open Access
- 1 December 2020
- Published by Elsevier in Papillomavirus Research
- Vol. 10, 100202
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
- 1 December 2020
- Published by Elsevier in Papillomavirus Research
- Vol. 10, 100202
Open AccessPrevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
- 1 November 2009
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 36 (11) , 696-703
Prevalence and Incidence of HPV Genital Infection in Women
A prophylactic quadrivalent human papillomavirus (HPV) vaccine could benefit adult women if they are susceptible to incident genital HPV infections and are acquiring new infections with vaccine HPV types to which they were previously not exposed. This report presents baseline and prospective data from a randomized, double-blind, placebo-controlled trial of the safety, immunogenicity, and efficacy of the quadrivalent HPV (Type 6/11/16/18) vaccine in women ages 24 to 45. We present the results of an epidemiologic analysis of 3730 women enrolled in a quadrivalent HPV vaccine efficacy trial between June 18, 2004 and April 30, 2008. Subjects were enrolled from 7 countries (Colombia, France, Germany, Philippines, Spain, Thailand, and the United States) through community and academic health centers and primary health care providers. Average baseline prevalence of anogenital infection and/or seropositivity was 32.8% for >or=1 vaccine HPV types and 0.3% for all vaccine HPV types. Incidence of anogential infection with any vaccine HPV type was approximately 10.5%. The rate of persistent infection was approximately 5% over a 30-month period among women in the placebo arm naïve to the relevant type at baseline. Predictors of incident infection included younger age, marital status other than first marriage, higher number of lifetime and recent sex partners, and Chlamydia/gonorrhea infection at baseline. These findings indicate that women up to age 45 are susceptible to vaccine HPV types and some are acquiring anogenital infections with vaccine HPV types. Future study concerning incident and prevalent HPV infection among women up to age 45 is warranted (Trial NCT number NCT00090220).
- 1 November 2009
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 36 (11) , 696-703
Prevalence and Incidence of HPV Genital Infection in Women
A prophylactic quadrivalent human papillomavirus (HPV) vaccine could benefit adult women if they are susceptible to incident genital HPV infections and are acquiring new infections with vaccine HPV types to which they were previously not exposed. This report presents baseline and prospective data from a randomized, double-blind, placebo-controlled trial of the safety, immunogenicity, and efficacy of the quadrivalent HPV (Type 6/11/16/18) vaccine in women ages 24 to 45. We present the results of an epidemiologic analysis of 3730 women enrolled in a quadrivalent HPV vaccine efficacy trial between June 18, 2004 and April 30, 2008. Subjects were enrolled from 7 countries (Colombia, France, Germany, Philippines, Spain, Thailand, and the United States) through community and academic health centers and primary health care providers. Average baseline prevalence of anogenital infection and/or seropositivity was 32.8% for >or=1 vaccine HPV types and 0.3% for all vaccine HPV types. Incidence of anogential infection with any vaccine HPV type was approximately 10.5%. The rate of persistent infection was approximately 5% over a 30-month period among women in the placebo arm naïve to the relevant type at baseline. Predictors of incident infection included younger age, marital status other than first marriage, higher number of lifetime and recent sex partners, and Chlamydia/gonorrhea infection at baseline. These findings indicate that women up to age 45 are susceptible to vaccine HPV types and some are acquiring anogenital infections with vaccine HPV types. Future study concerning incident and prevalent HPV infection among women up to age 45 is warranted (Trial NCT number NCT00090220).